Quick Answer
GUIDED THERAPEUTICS INC reported R&D Expense of $469.0 thousand for fiscal year 2025.
GUIDED THERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $469.0K | -10.8% |
| 2024 | $526.0K | +130.7% |
| 2023 | $228.0K | +196.1% |
| 2022 | $77.0K | +11.6% |
| 2021 | $69.0K | -51.7% |
| 2020 | $143.0K | +17.2% |
| 2019 | $122.0K | -50.0% |
| 2018 | $244.0K | -26.9% |
| 2017 | $334.0K | -54.4% |
| 2016 | $733.0K | -50.4% |
| 2015 | $1.48M | -47.0% |
| 2014 | $2.79M | +1.7% |
| 2013 | $2.74M | -15.0% |
| 2012 | $3.23M | +16.1% |
| 2011 | $2.78M | +54.0% |
| 2010 | $1.80M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $136.0K | +22.5% | +2.3% |
| June 30, 2025 | $133.0K | -40.1% | +79.7% |
| March 31, 2025 | $74.0K | +37.0% | -33.3% |
| September 30, 2024 | $111.0K | +60.9% | -50.0% |
| June 30, 2024 | $222.0K | +236.4% | +311.1% |
| March 31, 2024 | $54.0K | +671.4% | -21.7% |
| September 30, 2023 | $69.0K | +762.5% | +4.5% |
| June 30, 2023 | $66.0K | +633.3% | +842.9% |
- GUIDED THERAPEUTICS INC showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, GUIDED THERAPEUTICS INC’s r&d expense has declined by 74.0% (from $1.80 million to $469.0 thousand).
- The most recent figure is from GUIDED THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: